Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Lucence logo — Overcoming cancer through earlier detection

Lucence

Overcoming cancer through earlier detection

Founded 2016 United States Palo Alto, United States 111 employees Series A Total: $29.20M Biotechnology, Health Care

General Information

Company Name Lucence
Founded Year 2016
Location United States Palo Alto, United States +2
Employees 111
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when Lucence moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Lucence is currently recruiting for three open positions, signaling an active phase of team expansion to support its precision health operations. This hiring push, several years after their Series A funding in late 2019, suggests the company is strategically investing in growth or preparing for a significant next stage of development, likely involving a new fundraising round.

Signal Types
Hiring Funding
Strategic Labels
Team Expansion Growth Strategy Fundraising Readiness
Next Move: Fundraising
·
Impact: 7/10
·
Ideal For: Precision Health VCs – Growth Stage

About Lucence

Lucence, founded in 2016, is a pioneering venture in the Biotechnology and Health Care industries. The company stands out with its mission of Overcoming cancer through earlier detection. By leveraging proprietary AI-powered liquid biopsy technology, Lucence aims to detect cancers at an earlier stage, drastically improving patient outcomes.

Headquartered in both the United States and Singapore, Lucence operates through its twin CLIA-licensed laboratories, enhancing its capacity to provide personalized cancer care services internationally. This strategic geographic positioning enables it to serve a global market, tapping into cutting-edge healthcare innovation hubs.

The company's robust growth trajectory was underlined by a significant $20.00M Series A investment received on 01 November 2019. Notable investors include SGInnovate, Heliconia Capital, IHH Healthcare, Boon Hwee Koh, and Lim Kaling, indicating strong confidence in Lucence's technological potential and market strategy.

Taxonomy: Precision Health, Liquid Biopsy, AI-powered Technology, Cancer Detection, Personalized Cancer Care, Early Cancer Detection, Targeted Cancer Treatment, Proprietary Technology, Medical Diagnostics, CLIA-licensed Laboratories, Healthcare Innovation, Cancer Screening

Services & Products

LiquidHALLMARKse
LucenceINSIGHTse
CardioHemeRISK19
LucenceLONGEVITY19
HemeMARK19
UNITED 600
UNITED CNS
Rapid TissueMARK19

Target Customers

Oncologists Primary Care Doctors Patients Insurers Investors

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $20.00M 5
SGInnovate Heliconia Capital IHH Healthcare
Boon Hwee Koh, Lim Kaling 		01 Nov 2019
Seed $9.20M 3
Heliconia Capital
Boon Hwee Koh, Lim Kaling 		01 Jan 2019
Spinout Unknown 1
A*STAR
01 Apr 2016

Lucence Alternatives & Competitors

Lucence vs
Mirxes
Mirxes Singapore

To Know. To Act: Our mission is to save and improve lives through early, actionable, and personalize...

154 employees
Lucence vs
Endofotonics
Endofotonics Singapore

Identifying Early-stage Cancers Through In vivo Molecular Diagnosis

Series B
4 employees
Biotechnology, Health Care
Compare Lucence vs Endofotonics
Lucence vs
Seno Medical
Seno Medical United States

Groundbreaking diagnostic imaging for breast cancer using a novel combination of ultrasound and opto...

Series C
49 employees
Health Care, Medical Devices
Compare Lucence vs Seno Medical
Also compare with: Lucence vs SciBase SciBase Lucence vs Ezra Ezra

FAQ About Lucence

Overcoming cancer through earlier detection
Lucence was founded in 2016.
Lucence is headquartered in Palo Alto, United States.
Lucence operates in the following industries: Biotechnology, Health Care.
Lucence has approximately 111 employees.
Lucence has completed 3 funding rounds, raising a total of $29.20M. The latest funding stage is Series A.
Lucence offers: LiquidHALLMARKse, LucenceINSIGHTse, CardioHemeRISK19, LucenceLONGEVITY19, HemeMARK19, UNITED 600, UNITED CNS, Rapid TissueMARK19, LucenceMONITOR19.
Top alternatives and competitors to Lucence include Mirxes, Endofotonics, Seno Medical, SciBase, Numen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lucence and Mirxes are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Lucence and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy